Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NEXL -- Ignore unavailable to you. Want to Upgrade?

To: GREATMOOD who wrote (1378)	6/26/1998 7:23:00 AM
From: John Grabiec	Read Replies (1) \| Respond to of 1704

WOW, talk about inactivity! Anybody have anyhing, positive or negative, to say. It appears to me, that VMRX is needs the FDA approval on Isolex, or this puppy is worthless!

To: GREATMOOD who wrote (1378)	6/29/1998 6:10:00 PM
From: Mike Grove	Respond to of 1704

Acquisition of majority ownership in Nexell Therapeutics, a fully operational cell therapy company with current revenues and significant growth potential, gives me the confidence to say that the business prospects for VIMRX have never been better," Dunning said. ----------------------------------------- I guess the analysts and biotech investment community have completely overlooked this diamond in the rough..... HA !!!! If business has never looked better then why in the hell is the stock stuck in "park". This stock has done nothing in the last 2 years. They should start buying companies that market Herbs, vitamins, and other magic potions through health food stores. MAKE SUM DAMN MONEY !!!! One would think that if this company had some potential it would be trading at least in the 2.50 - 5.00 range. So Laura..... When can we see some movement from this supposed sleeping giant? Are you sure the giant isn't in a coma? Not happy about what I see, Mike